- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01348217
Radiochemotherapy With and Without Dose Escalation in Patients Presenting Locally Advanced or Inoperable Carcinoma of the Oesophagus (CONCORDE)
Prodige 26: Radiochemotherapy With and Without Dose Escalation in Patients Presenting Locally Advanced or Inoperable Carcinoma of the Oesophagus
Exclusive concomitant radiochemotherapy (RCT) at a dose of 50 Gy delivered over 5 weeks, according to the RTOG 85-01 protocol, has led to improved 5-year survival in 25% of patients, whereas no patients survived for 5 years using radiotherapy alone for patients with esophageal cancer. Surgery, even when combined with preoperative RCT, also gives disappointing results for locally advanced tumors, which casts serious doubts on the usefulness of preoperative radiotherapy. By varying the fractionation schedule, the length of treatment or the radiotherapy volumes, it has become possible to obtain levels of loco-regional relapse of around 35 to 45%. After reviewing the results for loco-regional relapse according to the dose of radiation and the recommended radiotherapy volumes, we aimed to investigate why increasing the dose of radiation has no impact in esophageal cancers. Although INT-0123 phase III trial showed no benefit of dose escalation in esophageal cancer, some issues remain unclear as most of the patients who died in the experimental arm were treated above 50Gy. Moreover, only the tumor was treated up to 64Gy while involved nodes were not considered for dose escalation in this trial. In the RTOG 85-01phase III trial, an elective nodal irradiation from subclavicular fossa up to the esophagogastric junction was performed with a 2D technique, delivering 30Gy which could be considered as not appropriate.
In this randomized phase II/III trial, we aim to test an exclusive concomitant chemoradiotherapy for patients with non resectable esophageal cancer with a dose escalation up to 66Gy on the primary tumor as well as the involved nodes using a 3D conformal technique combined with a 40 Gy elective nodal irradiation on lymph node stations (as defined by the RTOG) with a risk of microscopic involvement ≥ 20%.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Dijon, France, 21000
- Centre Georges François Leclerc
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age> or = 18 and < 75 ans
- WHO Status 0, 1 and 2
- Enteral or parenteral feeding (> or = 1500 KCal) planned before the start of treatment
- Histologically proven carcinoma of the oesophagus
- Histological Types: adenocarcinomas and epidermoid carcinomas
- T3, N0-N1-N2-N3, M0 (TNM version 7)
- T1-T2, N0-N1-N2-N3, M0 with a contra-indication for surgery (TNM version 7)
- Absence of trachea-oesophageal fistula
- Written informed consent
- Woman under appropriate contraception
- Patient able to understand and complete, with help if necessary, a quality of life questionnaire
Exclusion Criteria:
- Evolutive heart failure or myocardial necrosis for less than 6 months
- Myocardial infarction of more than 6 months with ischemic sequelae on myocardial scintigraphy.
- Patient cannot absorb at least 1500kcal/j before and/or during treatment
- Left heart failure.
- Stage II to IV arteriopathy in the Leriche and Fontaine classification
- Creatinine > or = 1.25x N
- PNN < 1,5.109 /l
- Platelets < 100. 109 /l
- Albumin < 30g/l
- TP < 60% without anticoagulant
- VEMS < 1l
- History of cancer (except baso-cellular cutaneous epithelioma or in situ epithelioma of the cervix) that has relapsed in the 5 years preceding recruitment for the trial
- Patient already enrolled in another therapeutic trial with an experimental molecule
- Women who are pregnant or likely to be so, or who are breastfeeding
- People who are in custody or under guardianship
- Impossibility to adhere to the medical follow up for the trial for geographical,social or psychiatric reasons.
- Presence of a history of radiotherapy to the chest or upper abdomen for another tumour
- Peripheral neuropathy > or = grade 1 (CTC v3.0)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: ARM A
Conformal 3D Radiotherapy with " ENI "-type prophylactic irradiation of the lymph nodes:
|
40 Gy in 20 fractions / 5 weeks, PTV (1cm in every direction)
Boost 10 Gy in 5 fr, PTV = +1cm.
Boost 26 Gy in 13 fr, PTV = +1cm.
6 treatments with 4 courses concomitant to radiotherapy (D1, D15, D29, D43) arm B or 3 courses concomitant to radiotherapy (D1, D15, D29) arm A.
|
Experimental: ARM B
Conformal 3D Radiotherapy with " ENI "-type prophylactic irradiation of the lymph nodes:
|
40 Gy in 20 fractions / 5 weeks, PTV (1cm in every direction)
Boost 10 Gy in 5 fr, PTV = +1cm.
Boost 26 Gy in 13 fr, PTV = +1cm.
6 treatments with 4 courses concomitant to radiotherapy (D1, D15, D29, D43) arm B or 3 courses concomitant to radiotherapy (D1, D15, D29) arm A.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evaluate the rate of acute toxicity leading to cessation or temporary interruption of treatment of more than a total of 14 days or of 7 consecutive days during the whole treatment.
Time Frame: end of phase II (january 2014)
|
end of phase II (january 2014)
|
Evaluate the rate of completes endoscopic response at 3 months
Time Frame: for each patient 3 months after the end treatment
|
for each patient 3 months after the end treatment
|
Survival without locoregional relapse at 2 years (time elapsed between date of randomisation and onset of local relapse and/or lymph node involvement)
Time Frame: after the end of phase III in january 2015 (anticipated)
|
after the end of phase III in january 2015 (anticipated)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate adherence
Time Frame: every 3 months until the end of phase II (january 2014)
|
every 3 months until the end of phase II (january 2014)
|
|
Evaluate acute toxicity at 3 months
Time Frame: for each patient 3 months after the end treatment
|
for each patient 3 months after the end treatment
|
|
Evaluate death due to toxicity
Time Frame: each month during all the study
|
each month during all the study
|
|
Evaluate quality of life (QLQ-C30 [annex n° 2] + OG25 [annex n° 3])
Time Frame: after the completion of phase II (january 2014)
|
after the completion of phase II (january 2014)
|
|
Compare according to treatment arm :Quality of life (QLQ-C30 [annex n° 2] + OG 25 [annex n° 3])
Time Frame: after the completion of phase III (january 2015-anticpated)
|
after the completion of phase III (january 2015-anticpated)
|
|
Compare according to treatment arm :Overall survival
Time Frame: after the completion of phase III (january 2015-anticpated)
|
after the completion of phase III (january 2015-anticpated)
|
|
Compare according to treatment arm :Disease-free survival
Time Frame: after the completion of phase III (january 2015-anticpated)
|
after the completion of phase III (january 2015-anticpated)
|
|
Compare according to treatment arm :Acute and late toxicity according to the CTCAE version 3.0 scale
Time Frame: after the completion of phase III (january 2015-anticpated)
|
after the completion of phase III (january 2015-anticpated)
|
|
Compare according to treatment arm :The number of palliative interventions, the time to the first palliative intervention
Time Frame: after the completion of phase III (january 2015-anticpated)
|
after the completion of phase III (january 2015-anticpated)
|
|
Compare according to treatment arm :The rate of dysphagia according to Atkinson's criteria
Time Frame: after the completion of phase III (january 2015-anticipated)
|
after the completion of phase III (january 2015-anticipated)
|
|
Compare according to treatment arm :Survival without local recurrence in responders
Time Frame: after the completion of phase III (january 2015-anticipated)
|
after the completion of phase III (january 2015-anticipated)
|
|
Compare according to treatment arm :Progression-free survival in non-responding patients
Time Frame: after the completion of phase III (january 2015-anticipated)
|
after the completion of phase III (january 2015-anticipated)
|
|
Evaluation of the post-operative morbi-mortalities
Time Frame: after the completion of phase III (january 2015-anticipated)
|
Evaluation of the post-operative morbi-mortalities (in 30 days) of the group of patients which will benefit from of a surgery of the tumoral residue.
|
after the completion of phase III (january 2015-anticipated)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Gilles Créhange, MD, Centre Georges François Leclerc
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0291-1crgi09
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Esophageal Cancer
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityWithdrawnStage IIB Esophageal Cancer AJCC v7 | Stage III Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IIIC Esophageal Cancer AJCC v7
-
National Cancer Institute (NCI)NRG OncologyCompletedEsophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Stage IIA Esophageal Cancer AJCC v7 | Stage IIB Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IB Esophageal Cancer AJCC v7United States
-
AIO-Studien-gGmbHBristol-Myers SquibbCompletedEsophageal Cancer | Gastrooesophageal Cancer | Oesophageal Cancer | GastroEsophageal Cancer | Esophageal Cancers NOS | Oesophageal Cancer Metastatic | Esophageal Cancer Metastatic | Oesophageal Cancer NosGermany
-
University of Wisconsin, MadisonActive, not recruitingResectable Esophageal Cancer | GastroEsophageal CancerUnited States
-
Cancer Institute and Hospital, Chinese Academy...Tianjin Medical University Cancer Institute and Hospital; Sichuan Cancer Hospital...UnknownEsophageal Neoplasm | Esophageal Cancer TNM Staging Primary Tumor (T) T3 | Esophageal Cancer TNM Staging Primary Tumor (T) T2 | Esophageal Cancer TNM Staging Regional Lymph Nodes (N) N0 | Esophageal Cancer TNM Staging Distal Metastasis (M) M0China
-
Tianjin Medical University Cancer Institute and...Sun Yat-sen University; Cancer Institute and Hospital, Chinese Academy of Medical... and other collaboratorsNot yet recruitingStage III Esophageal Cancer | Stage II Esophageal Cancer
-
Tianjin Medical University Cancer Institute and...UnknownStage III Esophageal Cancer | Stage II Esophageal CancerChina
-
Academisch Medisch Centrum - Universiteit van Amsterdam...UMC UtrechtCompletedEsophageal Cancer, Stage II | Esophageal Cancer Stage IIINetherlands
-
Tianjin Medical University Cancer Institute and...The First Affiliated Hospital with Nanjing Medical University; The First Affiliated... and other collaboratorsUnknownEsophageal Cancer Stage III | Esophageal Cancer Stage IIBChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedGastroesophageal Junction Adenocarcinoma | Stage IIA Esophageal Cancer AJCC v7 | Stage IIB Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IIIC Esophageal Cancer AJCC v7 | Malignant Neoplasm of the Cervical Esophagus | Malignant Neoplasm...United States
Clinical Trials on Conformal 3D Radiotherapy with " ENI "-type prophylactic irradiation of the lymph node
-
Lund University HospitalRecruiting
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI); NRG Oncology; Cancer and Leukemia Group BActive, not recruitingProstate CancerUnited States, Canada, China, Israel
-
University of WashingtonBlue Earth DiagnosticsRecruitingProstate AdenocarcinomaUnited States
-
National Cancer Institute (NCI)NRG OncologyRecruitingStage III Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Unresectable Lung Non-Small Cell Carcinoma | Locally Advanced Lung Non-Small Cell Carcinoma | Locally Recurrent Lung Non-Small Cell CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingRecurrent B Acute Lymphoblastic LeukemiaUnited States, Canada, Puerto Rico, Australia, New Zealand
-
National Cancer Institute (NCI)Active, not recruitingAdult T Acute Lymphoblastic Leukemia | Childhood T Acute Lymphoblastic Leukemia | Ann Arbor Stage II Adult Lymphoblastic Lymphoma | Ann Arbor Stage II Childhood Lymphoblastic Lymphoma | Ann Arbor Stage III Adult Lymphoblastic Lymphoma | Ann Arbor Stage III Childhood Lymphoblastic Lymphoma | Ann... and other conditionsUnited States, Canada, Australia, New Zealand